<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712709</url>
  </required_header>
  <id_info>
    <org_study_id>7212-03/2</org_study_id>
    <nct_id>NCT03712709</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test</brief_title>
  <official_title>Prospective, Multicentre Trial to Assess the Diagnostic Accuracy of the Truenat Assays at Intended Settings of Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Burnet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Research in Tuberculosis, Chennai, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ethiopian Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PD Hinduja Hospital and Medical Research Centre, Mumbai, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis
      will be interviewed for demographic and medical information, and then will be asked to
      provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested
      using conventional and investigational diagnostic tests for tuberculosis and rifampin
      resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay</measure>
    <time_frame>Day 1</time_frame>
    <description>Estimate diagnostic accuracy of the Truenat assays (MTB and MTB Plus) for Mycobacterium tuberculosis (MTB) detection among individuals undergoing evaluation for pulmonary TB, using a culture reference standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB-RIF Dx assay</measure>
    <time_frame>Day 1</time_frame>
    <description>Estimate diagnostic accuracy of the Truenat MTB-RIF Dx assay for RIF resistance detection among individuals undergoing evaluation for pulmonary TB and DR TB, using phenotypic/genotypic drug susceptibility testing (DST) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB assay compared to Xpert MTB/RIF</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare the diagnostic accuracy of the Truenat assays (MTB and MTB Plus) to that of Xpert MTB/RIF, using a reference standard of culture for TB diagnosis and phenotypic/genotypic DST for detection of RIF resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy (Sensitivity and Specificity) of the Truenat MTB-RIF Dx assay compared to Xpert MTB/RIF</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare the diagnostic accuracy of the Truenat MTB-RIF Dx assay to that of Xpert MTB/RIF, using a reference standard of culture for TB diagnosis and phenotypic/genotypic DST for detection of RIF resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to TB detection and RIF resistance detection.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess patient important outcomes, including time to detection of TB and RIF resistance.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1666</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Case Detection Group</arm_group_label>
    <description>Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Resistant TB Group</arm_group_label>
    <description>In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Truenat MTB</intervention_name>
    <description>The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.</description>
    <arm_group_label>Case Detection Group</arm_group_label>
    <arm_group_label>Drug Resistant TB Group</arm_group_label>
    <other_name>Truenat MTB Plus</other_name>
    <other_name>Truenat MTB-RIF Dx</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participant sputum may be retained for future research on TB diagnostics
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from outpatient TB clinics at district or regional health
        facilities. Given the important role of the private sector in India, 1 private laboratory
        will be included in the trial which is an MDR reference hospital.

        This is a multi-centre trial conducted in four countries: India, Peru, Papua New Guinea and
        Ethiopia. Countries were selected to be globally representative of the TB epidemic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Case Detection Group:

          -  Age 18 years or above

          -  Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other
             symptom typical of TB);

          -  Willingness to provide 3-4 sputum specimens at enrolment;

          -  Willingness to have a trial follow-up visit approximately 2 months after enrolment;

          -  Provision of informed consent.

        Drug Resistant TB Group:

        In addition to the criteria of the Case Detection Group, participants should also meet the
        following conditions:

          -  Non-converting pulmonary TB cases (category I and category II failures)

        Exclusion Criteria:

        Case Detection Group:

          -  Receipt of any dose of TB treatment within 60 days prior to enrolment (even if within
             last two days only).

        Drug Resistant TB Group:

          -  Receipt of any dose of MDR-TB treatment within 60 days prior to enrolment (even if
             within last two days only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Penn-Nicholson, PhD</last_name>
    <phone>+41 (22) 710 05 90</phone>
    <email>adam.penn-nicholson@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Nabeta, MD</last_name>
    <phone>+41 (22) 710 05 90</phone>
    <email>pamela.nabeta@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EPHI</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abyot Meaza</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State TB and Demonstration Center</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pranav Patel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIRT</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N S Gomathi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PD Hinduja Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Rodrigues</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ethiopia</country>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, Shetty A, Rodrigues C. Rapid diagnosis of Mycobacterium tuberculosis with Truenat MTB: a near-care approach. PLoS One. 2013;8(1):e51121. doi: 10.1371/journal.pone.0051121. Epub 2013 Jan 21.</citation>
    <PMID>23349670</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikam C, Kazi M, Nair C, Jaggannath M, M M, R V, Shetty A, Rodrigues C. Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. Int J Mycobacteriol. 2014 Sep;3(3):205-10. doi: 10.1016/j.ijmyco.2014.04.003. Epub 2014 Jun 2.</citation>
    <PMID>26786489</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03712709/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

